CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07Submission of Matters to a Vote of Security Holders.
completed its 2017 annual meeting of stockholders (the “Annual
Meeting”). The number of shares of common stock entitled to vote
at the Annual Meeting was 14,281,350 shares. The number of shares
of common stock present or represented by valid proxy at the
Annual Meeting was 9,384,155 shares. All matters submitted to a
vote of the Company’s stockholders at the Annual Meeting were
approved, and Chun Kwok Alan Au, Gang Ji and Bizuo (Tony) Liu
were elected Class II directors.
presented at the Annual Meeting:
elected for a term of three years, or until the election and
qualification of their successors.
|
Nominee
|
Shares Voted For
|
Shares Withheld
|
Broker Non-Vote
|
|||
|
Chun Kwok Alan Au
|
9,179,543
|
204,612
|
0
|
|||
|
Gang Ji
|
9,316,316
|
67,839
|
0
|
|||
|
Bizuo (Tony) Liu
|
9,301,819
|
82,336
|
0
|
Public Accountants LLP as the Companys independent registered
public accounting firm for the fiscal year ending December 31,
2017.
|
Shares Voted For
|
Shares Voted Against
|
Shares Abstaining
|
Broker Non-Vote
|
|||
|
9,316,279
|
67,666
|
210
|
0
|
Inc. 2014 Stock Incentive Plan to increase the number of shares
available for issuance thereunder by 1,000,000 shares.
|
Shares Voted For
|
Shares Voted Against
|
Shares Abstaining
|
Broker Non-Vote
|
|||
|
8,399,504
|
982,861
|
1,790
|
0
|
executive compensation.
|
Shares Voted For
|
Shares Voted Against
|
Shares Abstaining
|
Broker Non-Vote
|
|||
|
9,313,915
|
68,437
|
1,803
|
0
|
results of the Annual Meeting. A copy of the press release is
attached hereto as Exhibit 99.1.
About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases. CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Recent Trading Information
CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) closed its last trading session up +0.20 at 11.00 with 14,358 shares trading hands.
